Haw ParHAWPF 95 Pretax Margin % is 125.10% as of Dec. 2025, which is 48% above its 10-year median of 84.80. GuruFocus rates HAWPF with a GF Score™ of 95/100 and a GF Value™ of $8.94. The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Haw Par ranks better than 98.85% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Haw Par's Pre-Tax Income for the
six
months ended in Dec. 2025 was $100.4 Mil. Haw Par's Revenue for the
six
months ended in Dec. 2025 was $80.3 Mil. Therefore, Haw Par's pretax margin for the quarter that ended in Dec. 2025 was 125.10%.
The historical rank and industry rank for Haw Par's Pretax Margin % or its related term are showing as below:
HAWPF'
s Pretax Margin % Range Over the Past 10 Years
Min: 61.88 Med: 84.8 Max: 122.47
Current: 122.47
HAWPF's Pretax Margin % is ranked better than 98.85% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs HAWPF: 122.47
Haw Par (OTCPK:HAWPF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Haw Par Pretax Margin % Related Terms
Haw Par Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Haw Par's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAWPF vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Haw Par's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Haw Par's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haw Par (HAWPF) has a Pretax Margin % of 125.10% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Haw Par and its competitors. This is 48% above median its historical median of 84.80. Over the past decade, Haw Par's Pretax Margin % has ranged from 61.88 to 122.47. According to the industry distribution chart, Haw Par ranks #11 out of 955 companies in the Drug Manufacturers industry, placing it in the top 1.2%.
Is Haw Par's Pretax Margin % too high?
Haw Par's current Pretax Margin % of 125.10% is 48% above median its 10-year median of 84.80. Over the past 10 years, this metric has ranged from a low of 61.88 to a high of 122.47. The Drug Manufacturers industry median Pretax Margin % is 7.28. Haw Par's value of 125.10% is 1618.4% above this industry median. Based on the distribution chart, Haw Par ranks #11 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haw Par has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Haw Par's Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #11 out of 955 companies for Pretax Margin %. This places Haw Par in the top 1% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Haw Par's value of 125.10% is 1618.4% above this benchmark. Historically, Haw Par's own Pretax Margin % has ranged from 61.88 to 122.47 over the past decade. While the company's 10-year median is 84.80 vs. the industry median of 7.28, Haw Par has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current Pretax Margin % of 125.10% is 1618.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current Pretax Margin % is 125.10%, which is 48% above median its own 10-year median of 84.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Haw Par (HAWPF) has a current Pretax Margin % of 125.10%. The stock's GF Value™ is $8.94, compared to a current price of $12.00 — trading 34.2% above its estimated fair value. The current Pretax Margin % is 125.10%, which is 48% above median its 10-year median of 84.80 and 1618.4% above the Drug Manufacturers industry median of 7.28. Haw Par's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Haw Par (HAWPF), the current Pretax Margin % is 125.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.00 is trading 34.2% above its estimated GF Value™ of $8.94.
Key valuation signals for HAWPF:
Pretax Margin %: 125.10% (48% above median its 10-year median of 84.80)
GF Value™: $8.94 vs. price of $12.00 (34.2% above fair value)
Industry Position: 1618.4% above the Drug Manufacturers median (#11 of 955)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
95GF Score
Get the complete analysis for HAWPF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
